mammalian target of rapamycin

哺乳類ラパマイシン標的タンパク質

関

mTOR

同

mTOR

WordNet

1. intend (something) to move towards a certain goal; "He aimed his fists towards his opponents face"; "criticism directed at her superior"; "direct your anger towards others, not towards yourself" (同)aim, place, direct, point
2. sports equipment consisting of an object set up for a marksman or archer to aim at (同)butt
3. a reference point to shoot at; "his arrow hit the mark" (同)mark
4. the location of the target that is to be hit (同)target area
5. of or relating to the class Mammalia

PrepTutorEJDIC

1. 《所有・所属》…『の』,…のものである,…に属する・《材料・要素》…『でできた』,から成る・《部分》…『の』[『中の』] ・《数量・単位・種類を表す名詞に付いて》…の・《原因・動機》…『で』,のために(because of) ・《主格関係》…『の』,による,によって・《目的格関係》…『を』,の・《同格関係》…『という』・《関係・関連》…『についての』[『の』],の点で・《抽象名詞などと共に》…の[性質をもつ] ・《『It is』+『形』+『of』+『名』+『to』 doの形で,ofの後の名詞を意味上の主語として》・《分離》…『から』・《起原・出所》…『から』[『の』](out of) ・《『名』+『of』+『a』(『an』)+『名』の形で》…のような・《『名』+『of』+『mine』(『yours, his』など独立所有格)の形で》…の…・《時》(1)《副詞句を作って》…に《形容詞句を作って》…の・《時刻》《米》…前(to,《米》before)
2. (鉄砲などの)『標的』,的,攻撃目標 / (批評・軽べつなどの)的,種《+of+名》 / (行為などの)目標,到達目標
3. OLD French古[代]フランス語

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/11/20 14:29:16」(JST)

wiki en

[Wiki en表示]

Mechanistic target of rapamycin (serine/threonine kinase)
PDB rendering based on 1aue.
Available structures PDB Ortholog search: PDBe, RCSB List of PDB id codes 1AUE, 1FAP, 1NSG, 2FAP, 2GAQ, 2NPU, 2RSE, 3FAP, 4DRH, 4DRI, 4DRJ, 4FAP, 4JSN, 4JSP, 4JSV, 4JSX, 4JT5, 4JT6
Identifiers
Symbols	MTOR ; FRAP; FRAP1; FRAP2; RAFT1; RAPT1
External IDs	OMIM: 601231 MGI: 1928394 HomoloGene: 3637 ChEMBL: 2842 GeneCards: MTOR Gene
EC number	2.7.11.1
Gene ontology Molecular function • RNA polymerase III type 1 promoter DNA binding • RNA polymerase III type 2 promoter DNA binding • RNA polymerase III type 3 promoter DNA binding • TFIIIC-class transcription factor binding • protein serine/threonine kinase activity • protein binding • ATP binding • drug binding • kinase activity • protein domain specific binding • ribosome binding • protein dimerization activity • phosphoprotein binding Cellular component • Golgi membrane • nucleoplasm • cytoplasm • mitochondrial outer membrane • lysosome • lysosomal membrane • endoplasmic reticulum membrane • cytosol • phosphatidylinositol 3-kinase complex • endomembrane system • membrane • PML body • dendrite • TORC1 complex • TORC2 complex • neuronal cell body Biological process • double-strand break repair via homologous recombination • positive regulation of protein phosphorylation • positive regulation of endothelial cell proliferation • regulation of glycogen biosynthetic process • 'de novo' pyrimidine nucleobase biosynthetic process • transcription initiation from RNA polymerase II promoter • protein phosphorylation • response to stress • cell cycle arrest • signal transduction • epidermal growth factor receptor signaling pathway • germ cell development • response to nutrient • insulin receptor signaling pathway • fibroblast growth factor receptor signaling pathway • gene expression • negative regulation of autophagy • positive regulation of lamellipodium assembly • positive regulation of gene expression • positive regulation of myotube differentiation • cell growth • negative regulation of macroautophagy • phosphorylation • peptidyl-serine phosphorylation • peptidyl-threonine phosphorylation • protein catabolic process • positive regulation of actin filament polymerization • T cell costimulation • ruffle organization • regulation of myelination • cellular response to nutrient levels • TOR signaling • regulation of fatty acid beta-oxidation • regulation of response to food • regulation of actin cytoskeleton organization • cellular response to heat • Fc-epsilon receptor signaling pathway • growth • regulation of GTPase activity • response to amino acid • regulation of carbohydrate utilization • innate immune response • regulation of osteoclast differentiation • positive regulation of translation • negative regulation of cell size • regulation of protein kinase activity • positive regulation of transcription from RNA polymerase III promoter • protein autophosphorylation • positive regulation of lipid biosynthetic process • vascular endothelial growth factor receptor signaling pathway • neurotrophin TRK receptor signaling pathway • phosphatidylinositol-mediated signaling • positive regulation of peptidyl-tyrosine phosphorylation • positive regulation of stress fiber assembly • negative regulation of NFAT protein import into nucleus • positive regulation of protein kinase B signaling • cardiac cell development • cellular response to hypoxia • regulation of cellular response to heat • negative regulation of mitochondrion degradation Sources: Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	2475	56717
Ensembl	ENSG00000198793	ENSMUSG00000028991
UniProt	P42345	Q9JLN9
RefSeq (mRNA)	NM_004958	NM_020009
RefSeq (protein)	NP_004949	NP_064393
Location (UCSC)	Chr 1: 11.11 – 11.26 Mb	Chr 4: 148.45 – 148.56 Mb
PubMed search	[2]	[3]

The mechanistic target of rapamycin, also known as mammalian target of rapamycin (mTOR) or FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a protein that in humans is encoded by the MTOR gene. MTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and transcription. MTOR belongs to the phosphatidylinositol 3-kinase-related kinase protein family.

Discovery

MTOR was first named as the mammalian target of rapamycin. Rapamycin was discovered in a soil sample from Easter Island, known locally as Rapa Nui, in the 1970s. The bacterium Streptomyces hygroscopicus, isolated from that sample, produces an antifungal that researchers named rapamycin after the island.

Rapamycin arrests fungal activity at the G1 phase of the cell cycle. In mammals, it suppresses the immune system by blocking the G1 to S phase transition in T-lymphocytes. Thus, it is used as an immunosuppressant following organ transplantation.

Molecular genetic studies in yeast (published in 1991) first identified FKBP12, TOR1, and TOR2 as the targets of rapamycin; these studies were conducted at the Biozentrum in Basel, Switzerland and Sandoz Pharmaceuticals (now Novartis) by Joseph Heitman, Rao Movva, and Michael N. Hall. They isolated rapamycin-resistant mutants of Saccharomyces cerevisiae and discovered that mutations in any of three genes can confer rapamycin resistance. Two of the genes were named TOR1 and TOR2 for targets of rapamycin (TOR) and in honor of the Spalentor, a gate to the city of Basel where TOR was first discovered. The third gene is FPR1, which encodes the yeast ortholog of FKBP12 binding protein in the TOR complexes. Loss of function mutations in FPR1 confer resistance to rapamycin, and also to FK506, providing genetic evidence the FKBP12-drug complexes are the active intracellular agents. Mutations in TOR1 or TOR2 that confer FKBP12-rapamycin resistance are dominant gain of function mutations that alter single amino acid residues within the FRB domain and thereby block FKBP12-rapamycin binding. Several years later, in 1994 the mammalian target of rapamycin (mTOR) was identified and found to be the ortholog of the yeast Tor1/2 proteins and defined as the rapamycin target in mammals by David M. Sabatini and Solomon H. Snyder (Johns Hopkins University) and also by Robert Abraham (who first named it mTOR) and Stuart L. Schreiber (Harvard University). mTOR stands for mammalian Target Of Rapamycin and was named based on the precedent that TOR was first discovered via genetic and molecular studies of rapamycin-resistant mutants of Saccharomyces cerevisiae that identified Tor1 and Tor2 as the targets of rapamycin.

Function

MTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12. The FKBP12-rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.

Complexes

MTOR is the catalytic subunit of two structurally distinct complexes: mTORC1 and mTORC2. Both complexes localize to different subcellular compartments, thus affecting their activation and function.

mTORC1

Main article: mTORC1

mTOR Complex 1 (mTORC1) is composed of MTOR, regulatory-associated protein of MTOR (Raptor), mammalian lethal with SEC13 protein 8 (MLST8) and the non-core components PRAS40 and DEPTOR. This complex functions as a nutrient/energy/redox sensor and controls protein synthesis. The activity of mTORC1 is stimulated by insulin, growth factors, serum, phosphatidic acid, amino acids (particularly leucine), and oxidative stress.

mTORC2

Main article: mTORC2

mTOR Complex 2 (mTORC2) is composed of MTOR, rapamycin-insensitive companion of MTOR (RICTOR), MLST8, and mammalian stress-activated protein kinase interacting protein 1 (mSIN1). mTORC2 has been shown to function as an important regulator of the cytoskeleton through its stimulation of F-actin stress fibers, paxillin, RhoA, Rac1, Cdc42, and protein kinase C α (PKCα). mTORC2 also phosphorylates the serine/threonine protein kinase Akt/PKB at the serine residue S473 , thus affecting metabolism and survival. Phosphorylation of the serine stimulates Akt phosphorylation at a threonine T308 residue by PDK1 and leads to full Akt activation;

Inhibition by rapamycin

Rapamycin inhibits mTORC1, and this appears to provide most of the beneficial effects of the drug (including life-span extension in animal studies). Rapamycin has a more complex effect on mTORC2, inhibiting it only in certain cell types under prolonged exposure. Disruption of mTORC2 produces the diabetic-like symptoms of decreased glucose tolerance and insensitivity to insulin.

Gene deletion experiments

The mTORC2 signaling pathway is less defined than the mTORC1 signaling pathway. The functions of the components of the mTORC complexes have been studied using knockdowns and knockouts and were found to produce the following phenotypes:

• NIP7: Knockdown reduced mTORC2 activity that is indicated by decreased phosphorylation of mTORC2 substrates.
• RICTOR: Overexpression leads to metastasis and knockdown inhibits growth factor-induced PKC-phosphorylation.
• mTOR: Inhibition of mTORC1 and mTORC2 by PP242 [2-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol] leads to autophagy or apoptosis; inhibition of mTORC2 alone by PP242 prevents phosphorylation of Ser-473 site on AKT and arrests the cells in G1 phase of the cell cycle.
• PDK1: Knockout is lethal; hypomorphic allele results in smaller organ volume and organism size but normal AKT activation.
• AKT: Knockout mice experience spontaneous apoptosis (AKT1), severe diabetes (AKT2), small brains (AKT3), and growth deficiency (AKT1/AKT2)
• TOR1, the S. cerevisiae orthologue of mTORC1, is a regulator of both carbon and nitrogen metabolism; TOR1 KO strains regulate response to nitrogen as well as carbon availability, indicating that it is a key nutritional transducer in yeast.

Clinical significance

Autism

MTOR is implicated in the failure of a 'pruning' mechanism of the excitatory synapses in autism spectrum disorders.

Aging

mTOR signaling pathway.[1]

Decreased TOR activity has been found to increase life span in S. cerevisiae, C. elegans, and D. melanogaster. The mTOR inhibitor rapamycin has been confirmed to increase lifespan in mice by independent groups at the Jackson Laboratory, University of Texas Health Science Center, and the University of Michigan.

It is hypothesized that some dietary regimes, like caloric restriction and methionine restriction, cause lifespan extension by decreasing mTOR activity. It is believed that this is achieved by limiting the essential amino acid leucine, a potent activator of mTOR. The administration of leucine into the rat brain has been shown to decrease food intake and body weight via activation of the mTOR pathway.

According to the free radical theory of aging, reactive oxygen species cause damage of mitochondrial proteins and decrease of ATP production. Subsequently, via ATP sensitive AMPK, the mTOR pathway is inhibited and ATP consuming protein synthesis is downregulated, since mTORC1 initiates a phosphorylation cascade activating the ribosome. Hence, the proportion of damaged proteins is enhanced. Moreover, disruption of mTORC1 directly inhibits mitochondrial respiration. These positive feedbacks on the aging process are counteracted by protective mechanisms: Decreased mTOR activity (among other factors) upregulates glycolysis and removal of dysfunctional cellular components via autophagy.

Alzheimer’s disease

mTOR signaling intersects with Alzheimer’s disease (AD) pathology in several aspects, suggesting its potential role as a contributor to disease progression. In general, findings demonstrate mTOR signaling hyperactivity in AD brains. For example, postmortem studies of human AD brain reveal dysregulation in PTEN, Akt, S6K, and mTOR. mTOR signaling appears to be closely related to the presence of soluble amyloid beta (Aβ) and tau proteins, which aggregate and form two hallmarks of the disease, Aβ plaques and neurofibrillary tangles, respectively. In vitro studies have shown Aβ to be an activator of the PI3K/AKT pathway, which in turn activates mTOR. In addition, applying Aβ to N2K cells increases the expression of p70S6K, a downstream target of mTOR known to have higher expression in neurons that eventually develop neurofibrillary tangles. Chinese hamster ovary cells transfected with the 7PA2 familial AD mutation also exhibit increased mTOR activity compared to controls, and the hyperactivity is blocked using a gamma-secretase inhibitor. These in vitro studies suggest that increasing Aβ concentrations increases mTOR signaling; however, significantly large, cytotoxic Aβ concentrations are thought to decrease mTOR signaling.

Consistent with data observed in vitro, mTOR activity and activated p70S6K have been shown to be significantly increased in the cortex and hippocampus of animal models of AD compared to controls. Pharmacologic or genetic removal of the Aβ in animal models of AD eliminates the disruption in normal mTOR activity, pointing to the direct involvement of Aβ in mTOR signaling. In addition, by injecting Aβ oligomers into the hippocampi of normal mice, mTOR hyperactivity is observed. Cognitive impairments characteristic of AD appear to be mediated by the phosphorylation of PRAS-40, which detaches from and allows for the mTOR hyperactivity when it is phosphorylated; inhibiting PRAS-40 phosphorylation prevents Aβ-induced mTOR hyperactivity. Given these findings, the mTOR signaling pathway appears to be one mechanism of Aβ-induced toxicity in AD.

The hyperphosphorylation of tau proteins into neurofibrillary tangles is one hallmark of AD. p70S6K activation has been shown to promote tangle formation as well as mTOR hyperactivity through increased phosphorylation and reduced dephosphorylation. It has also been proposed that mTOR contributes to tau pathology by increasing the translation of tau and other proteins.

Synaptic plasticity is a key contributor to learning and memory, two processes that are severely impaired in AD patients. Translational control, or the maintenance of protein homeostasis, has been shown to be essential for neural plasticity and is regulated by mTOR. Both protein over- and under-production via mTOR activity seem to contribute to impaired learning and memory. Furthermore, given that deficits resulting from mTOR overactivity can be alleviated through treatment with rapamycin, it is possible that mTOR plays an important role in affecting cognitive functioning through synaptic plasticity. Further evidence for mTOR activity in neurodegeneration comes from recent findings demonstrating that eIF2α-P, an upstream target of the mTOR pathway, mediates cell death in prion diseases through sustained translational inhibition.

Some evidence points to mTOR’s role in reduced Aβ clearance as well. mTOR is a negative regulator of autophagy; therefore, hyperactivity in mTOR signaling should reduce Aβ clearance in the AD brain. Several groups have proposed that disruptions in autophagy may be a potential source of pathogenesis in protein misfolding diseases, including AD. Studies using mouse models of Huntington’s disease demonstrate that treatment with rapamycin facilitates the clearance of huntingtin aggregates. Perhaps the same treatment may be useful in clearing Aβ deposits as well.

Cancer

Over-activation of mTOR signaling significantly contributes to the initiation and development of tumors and mTOR activity was found to be deregulated in many types of cancer including breast, prostate, lung, melanoma, bladder, brain, and renal carcinomas. Reasons for constitutive activation are several. Among the most common are mutations in tumor suppressor PTEN gene. PTEN phosphatase negatively affects mTOR signalling through interfering with the effect of PI3K, an upstream effector of mTOR. Additionally, mTOR activity is deregulated in many cancers as a result of increased activity of PI3K or Akt. Similarly, overexpression of downstream mTOR effectors 4E-BP1, S6K and eIF4E leads to poor cancer prognosis. Also, mutations in TSC protein that inhibits the activity of mTOR may lead to a condition named tuberous sclerosis complex, which exhibits as benign lesions and increases the risk of renal cell carcinoma.

Increasing mTOR activity was shown to drive cell cycle progression and increase cell proliferation mainly thanks to its effect on protein synthesis. Moreover, active mTOR supports tumor growth also indirectly by inhibiting autophagy. Constitutively activated mTOR functions in supplying carcinoma cells with oxygen and nutrients by increasing the translation of HIF1A and supporting angiogenesis. mTOR also aids in another metabolic adaptation of cancerous cells to support their increased growth rate - activation of glycolytic metabolism. Akt2, a substrate of mTOR, specifically of mTORC2, upregulates expression of the glycolytic enzyme PKM2 thus contributing to the Warburg effect.

mTOR inhibitors as therapies

Main article: mTOR inhibitors

mTOR inhibitors, e.g. rapamycin, are already used to prevent transplant rejection. Rapamycin is also related to the therapy of glycogen storage disease (GSD). Some articles reported that rapamycin can inhibit mTORC1 so that the phosphorylation of GS(glycogen synthase) can be increased in skeletal muscle. This discovery represents a potential novel therapeutic approach for glycogen storage diseases that involve glycogen accumulation in muscle. Various natural compounds, including epigallocatechin gallate (EGCG), caffeine, curcumin, and resveratrol, have also been reported to inhibit mTOR when applied to isolated cells in culture; however, there is as yet no evidence that these substances inhibit mTOR when taken as dietary supplements.

Some mTOR inhibitors (e.g. temsirolimus, everolimus) are beginning to be used in the treatment of cancer. mTOR inhibitors may also be useful for treating several age-associated diseases including neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Ridaforolimus is another mTOR inhibitor, currently in clinical development.

Interactions

Mammalian target of rapamycin has been shown to interact with:

• ABL1,
• AKT1,
• CLIP1,
• EIF3F
• EIF4EBP1,
• FKBP1A,
• GPHN,
• KIAA1303,
• PRKCD,
• RHEB,
• RICTOR,
• RPS6KB1,
• STAT1,
• STAT3, and
• UBQLN1.

References

External links

• mTOR protein at the US National Library of Medicine Medical Subject Headings (MeSH)
• "mTOR Signaling Pathway in Pathway Interaction Database". National Cancer Institute. 

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 腎移植における哺乳動物ラパマイシン標的蛋白質（mTOR）阻害剤 mammalian target of rapamycin mtor inhibitors in renal transplantation
• 2. 進行腎明細胞癌または転移性腎明細胞癌に対する抗血管新生療法および分子標的療法 anti angiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal cell carcinoma
• 3. 結節性硬化症：遺伝学、臨床的特徴、および診断 tuberous sclerosis complex genetics clinical features and diagnosis
• 4. 成人における肝移植：免疫抑制の概要 liver transplantation in adults overview of immunosuppression
• 5. 結節性硬化症の腎症状 renal manifestations of tuberous sclerosis complex

English Journal

• The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas.

• Argyriou P, Economopoulou P, Papageorgiou S.SourceDepartment of Pathology, "Evangelismos" General Hospital of Athens, Athens, Greece.
• Advances in hematology.Adv Hematol.2012;2012:435342. Epub 2011 Jun 16.
• Despite the fact that the majority of lymphomas initially respond to treatment, many patients relapse and die from disease that is refractory to current regimens. The need for new treatment strategies in lymphomas has led to the investigation and evaluation of novel agents that target cellular pathw
• PMID 21822434

• Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53.

• Jing K, Song KS, Shin S, Kim N, Jeong S, Oh HR, Park JH, Seo KS, Heo JY, Han J, Park JI, Han C, Wu T, Kweon GR, Park SK, Yoon WH, Hwang BD, Lim K.SourceDepartment of Biochemistry; College of Medicine; Infection Signaling Network Research Center; Chungnam National University; Daejeon, Korea.
• Autophagy.Autophagy.2011 Nov 1;7(11). [Epub ahead of print]
• Docosahexaenoic acid (DHA) has been reported to induce tumor cell death by apoptosis. However, little is known about the effects of DHA on autophagy, another complex well-programmed process characterized by the sequestration of cytoplasmic material within autophagosomes. Here, we show that DHA incre
• PMID 21811093

Japanese Journal

• The β-carboline alkaloid harmol induces cell death via autophagy but not apoptosis in human non-small cell lung cancer A549 cells

• Abe Akihisa,Yamada Hiroyuki,Moriya Shota [他]
• Biological & pharmaceutical bulletin 34(8), 1264-1272, 2011-08
• NAID 40018914014

• 転移性腎癌に対するmTOR阻害薬--temsirolimus (AYUMI 腎細胞癌の分子標的治療)

• 植田 健,深沢 賢
• 医学のあゆみ 236(12), 1111-1115, 2011-03-19
• NAID 40018712209

Related Links

• Mammalian target of rapamycin - Wikipedia, the free encyclopedia

The mammalian target of rapamycin (mTOR) also known as mechanistic target of rapamycin or FK506 binding protein 12-rapamycin associated protein 1 (FRAP1) is a protein which in humans is encoded by the FRAP1 gene. mTOR is a ...

Related Pictures

---

★リンクテーブル★

リンク元	「mTOR」「哺乳類ラパマイシン標的タンパク質」
関連記事	「target」「targeting」「mammalian」「rapamycin」

「mTOR」

　　[★]

• 哺乳類ラパマイシン標的タンパク質

関

mammalian target of rapamycin

「哺乳類ラパマイシン標的タンパク質」

　　[★]

英

mammalian target of rapamycin、mTOR

「target」

　　[★]

• n.

• 標的、的、ターゲット

• v.

• 標的にする

　 　 　 　 　

「targeting」

　　[★]

ターゲティング、標的指向化

「mammalian」

　　[★]

• 哺乳類の

関

mammal

　

「rapamycin」

　　[★] シロリムス

同

mTOR